Healthcare Industry News: Novo Ventures
News Release - May 17, 2010
AxoGen Names Karen Zaderej as Chief Executive OfficerALACHUA, Fla.--(HSMN NewsFeed)--AxoGen, Inc. announced today the promotion of Karen Zaderej to the position of Chief Executive Officer. Ms. Zaderej was formerly the Chief Operating Officer. Former AxoGen CEO, Jamie Grooms has retained the role of Chairman of the Board for AxoGen.
Ms. Zaderej has been instrumental in the successful development and launch of the AxoGen portfolio of nerve products for bridging, connecting and protecting peripheral nerves: Avance® Nerve Graft, AxoGuard® Nerve Connector, and AxoGuard® Nerve Protector. To accomplish this, she has overseen strategic partnerships, taken the company international and managed costs.
“As the part of the long term vision and plans for AxoGen, Ms. Zaderej has been named as Chief Executive Officer to lead AxoGen into its next phase of corporate growth as we expand into new markets and continue to develop products that improve the lives of patients with peripheral nerve injuries,” said Jamie Grooms, Chairman and co-founder of AxoGen.
Ms. Zaderej has more than 20 years of experience in the medical device and tissue markets. At Ethicon, a Johnson & Johnson company, she held senior positions in Marketing, Business Development, and R&D as well as ran a manufacturing business. After leaving J&J, she started Zaderej Medical Consulting to assist medical device companies build and execute winning commercialization plans. She has an MBA from the Kellogg Graduate School of Business and a BS in Chemical Engineering from Purdue University.
AxoGen, Inc. is a privately held company working to develop new and more effective products to treat peripheral nerve damage. With the focus of bringing the science of nerve repair to life, AxoGen is working to introduce new technologies to improve the standard of care to patients with injured peripheral nerves. With licensed technologies from the University of Florida, the University of Texas, and Emory University, researchers at AxoGen have developed an innovative technology platform making it possible to process allograft nerves while preserving the relevant characteristics of the three dimensional scaffold of the nerve tissue. Based in Alachua, Florida, AxoGen has received funding from private investors including Accuitive Medical Ventures, Cardinal Partners, De Novo Ventures, Springboard Capital II, LLC, SynoGen, and Emergent Growth Fund of Gainesville, FL.
AxoGen is a registered tissue establishment with the FDA.
Visit AxoGen at: www.axogeninc.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.